A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Prostate Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/5/2019 |
| Start Date: | February 21, 2018 |
| End Date: | February 18, 2022 |
| Contact: | There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or |
| Email: | clinicaltrials.gov@lilly.com |
| Phone: | 1-317-615-4559 |
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
The purpose of this study is to evaluate the safety of the study drug LY3381916 administered
alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody
(LY3300054).
alone or in combination with anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody
(LY3300054).
Inclusion Criteria:
- Participant must have histological or cytological evidence of a diagnosis of cancer
that is advanced and/or metastatic.
- Have adequate organ function.
- Have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG)
scale.
- Have discontinued previous treatments for cancer.
- Are able to swallow capsules.
Exclusion Criteria:
- Currently enrolled in a clinical study.
- Have a serious concomitant systemic disorder.
- Have a symptomatic human immunodeficiency virus infection or symptomatic
activated/reactivated hepatitis B or C.
- Have a significant cardiac condition.
- Have previously received an indoleamine- 2,3-dioxygenase (IDO) inhibitor.
We found this trial at
4
sites
121 Boulevard de Waterloo
Brussel, 1000
Brussel, 1000
Principal Investigator: Nuria Kotecki
Phone: 3225413059
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Bert H O'Neil
Phone: 317-278-8845
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: SMO Sarah Cannon Research Inst.
Phone: 615-329-7615
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
Nashville, Tennessee 37023
615-320-5090
Principal Investigator: Johanna Chock Bendell
Phone: 6153297274
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
Click here to add this to my saved trials